Ghrelin modulates physiologic and pathologic retinal angiogenesis through GHSR-1a

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 8, 2011, Pages 5376-5386

  Zaniolo, Karine ^a   Sapieha, Przemyslaw ^b   Shao, Zhuo ^a,c   Stahl, Andreas ^d,e   Zhu, Tang ^a   Tremblay, Sophie ^a   Picard, Emilie ^a   Madaan, Ankush ^a,c   Blais, Martine ^a   Lachapelle, Pierre ^f   Mancini, Joseph ^c   Hardy, Pierre ^a   Smith, Lois E H ^e   Ong, Huy ^g   Chemtob, Sylvain ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF FREIBURG   (Germany)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f MONTREAL CHILDREN S HOSPITAL   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; GHRELIN RECEPTOR; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN; INSULIN LIKE GROWTH FACTOR 1, RAT; INSULIN-LIKE GROWTH FACTOR-1, RAT; OXYGEN; SOMATOMEDIN C; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL OCCLUSION; CELL GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLANT; HYPEROXIA; IMMUNOHISTOCHEMISTRY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA; RETINA NEOVASCULARIZATION; RETINOPATHY; SWINE; WESTERN BLOTTING; ANIMAL; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; CULTURE TECHNIQUE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; RETINA BLOOD VESSEL; RETROLENTAL FIBROPLASIA; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GHRELIN; HUMANS; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR I; INTRAVITREAL INJECTIONS; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; OXYGEN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GHRELIN; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052814913     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-7152     Document Type: Article

References (46)

1. Sapieha P, et al. Proliferative retinopathies: angiogenesis that blinds. Int J Biochem Cell Biol. 2010;42:5-12.
2. Sapieha P, et al. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest. 2010;120:3022-3032.
3. Shiiya T, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 2002;87:240-244.
4. Lee HM, Wang G, Englander EW, Kojima M, Greeley GH Jr. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology. 2002;143:185-190.
5. Adeghate E, Ponery AS. Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. J Neuroendocrinol. 2002;14:555-560.
6. Ueno H, Shiiya T, Mizuta M, Mondal SM, Nakazato M. Plasma ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics. Endocr J. 2007;54:895-902.
7. Simons BD, Flynn JT. Retinopathy of prematurity and associated factors. Int Ophthalmol Clin. 1999;39:29-48.
8. Hellstrom A, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 2001;98:5804-5808.
9. Smith LE, et al. Essential role of growth hormone in ischemiainduced retinal neovascularization. Science. 1997;276:1706-1709.
10. Smith LE, et al. Regulation of vascular endothelial growth factordependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med. 1999;5:1390-1395.
11. Aiello LP, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
12. Aiello LP, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457-10461.
13. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008;118: 526-533.
14. Chen J, et al. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci. 2009;50:1329-1335.
15. Dembinski A, et al. Variable effect of ghrelin administration on pancreatic development in young rats: role of insulin-like growth factor-1. J Physiol Pharmacol. 2005;56:555-570.
16. Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660.
17. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005;85:495-522.
18. Li WG, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation. 2004;109:2221-2226.
19. Baldanzi G, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol. 2002;159:1029-1037.
20. Li A, Cheng G, Zhu GH, Tarnawski AS. Ghrelin stimulates angiogenesis in human microvascular endothelial cells: implications beyond GH release. Biochem Biophys Res Commun. 2007;353: 238-243.
21. Rocha De Sousa A, Ramos-Tavares M, Teles A, Leite-Moreira AF. Ghrelin's mRNA levels in the developing rat's eye. Acta Ophthalmol. 2008;86:0. doi: 10.1111/j.1755-3768.2008.402.x.
22. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci. 1993;34:576-585.
23. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res. 1994;36:724-731.
24. Dorfman A, Dembinska O, Chemtob S, Lachapelle P. Early manifestations of postnatal hyperoxia on the retinal structure and function of the neonatal rat. Invest Ophthalmol Vis Sci. 2008;49: 458-466.
25. Stahl A, et al. Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy. Am J Pathol. 2010;177:2715-2723.
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem. 1976;72:248-254.
27. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76:4350-4354.
28. Burnette WN. "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 1981;112:195-203.
29. Davenport AP, et al. International Union of Pharmacology, LVI: ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev. 2005;57:541-546.
30. Cassoni P, et al. Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue. J Endocrinol. 2000;165:139-146.
31. Zizzari P, et al. Endogenous ghrelin regulates episodic growth hormone (GH) secretion by amplifying GH pulse amplitude: evidence from antagonism of the GH secretagogue-R1a receptor. Endocrinology. 2005;146:3836-3842.
32. Ricci B, Lepore D, Zonghi E, Calogero G. Oxygen-induced retinopathy in the newborn rat: a scoring system for the evaluation of retinal vascular changes: scoring system for OIR in the rat. Doc Ophthalmol. 1990;76:241-249.
33. Banin E, et al. T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification. Invest Ophthalmol Vis Sci. 2006;47:2125-2134.
34. Gebarowska D, et al. Synthetic peptides interacting with the 67-kd laminin receptor can reduce retinal ischemia and inhibit hypoxiainduced retinal neovascularization. Am J Pathol. 2002;160:307-313.
35. Connor KM, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009;4:1565-1573.
36. Coward P, et al. Controlling signaling with a specifically designed Gi-coupled receptor. Proc Natl Acad Sci U S A. 1998;95:352-357.
37. Sennlaub F, et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation. 2003;108:198-204.
38. Higgins RD, et al. Diltiazem reduces retinal neovascularization in a mouse model of oxygen induced retinopathy. Curr Eye Res. 1999;18:20-27.
39. Sapieha P, et al. The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat Med. 2008;14:1067-1076.
40. Lofqvist C, et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci U S A. 2007;104:10589-10594.
41. Smith LE. Through the eyes of a child: understanding retinopathy through ROP: the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49:5177-5182.
42. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10:133-140.
43. Lofqvist C, et al. Quantification and localization of the IGF/insulin system expression in retinal blood vessels and neurons during oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci. 2009;50:1831-1837.
44. Sapieha P, et al. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest. 120:3022-3032.
45. Smith L. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003;8:469-473.
46. Stahl A, et al. Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema. Retina. 30:1524-1529.